Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) Net Margin: 2011-2025

Historic Net Margin for Ani Pharmaceuticals (ANIP) over the last 15 years, with Sep 2025 value amounting to 11.53%.

  • Ani Pharmaceuticals' Net Margin rose 2810.00% to 11.53% in Q3 2025 from the same period last year, while for Sep 2025 it was 4.72%, marking a year-over-year increase of 629.00%. This contributed to the annual value of -3.28% for FY2024, which is 680.00% down from last year.
  • Ani Pharmaceuticals' Net Margin amounted to 11.53% in Q3 2025, which was up 199.40% from 3.85% recorded in Q2 2025.
  • Ani Pharmaceuticals' Net Margin's 5-year high stood at 12.95% during Q1 2024, with a 5-year trough of -39.93% in Q4 2021.
  • In the last 3 years, Ani Pharmaceuticals' Net Margin had a median value of 3.85% in 2025 and averaged 2.34%.
  • Its Net Margin has fluctuated over the past 5 years, first plummeted by 3,361bps in 2021, then soared by 3,499bps in 2022.
  • Over the past 5 years, Ani Pharmaceuticals' Net Margin (Quarterly) stood at -39.93% in 2021, then soared by 3,499bps to -4.93% in 2022, then soared by 550bps to 0.57% in 2023, then tumbled by 617bps to -5.61% in 2024, then spiked by 2,810bps to 11.53% in 2025.
  • Its Net Margin was 11.53% in Q3 2025, compared to 3.85% in Q2 2025 and 7.75% in Q1 2025.